PINP as a biological response marker during teriparatide treatment for osteoporosis

J. H. Krege, Nancy E Lane, J. M. Harris, P. D. Miller

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Postmenopausal women with severe osteoporosis may require treatment with the bone anabolic drug teriparatide. While changes in bone mineral density (BMD) are one measure of response, BMD changes often require a minimum of one year to observe measureable changes. Biochemical markers of bone turnover change within 1 to 3 months of initiating osteoporosis therapy. Monitoring with a marker such as procollagen type I N propeptide (PINP), an osteoblast-derived protein, during teriparatide treatment may provide clinically useful information for managing patients with osteoporosis. Clinical trials have shown consistent increases in PINP within 3 months of initiating teriparatide, increases that are significantly greater than placebo and significantly different from baseline. Increases in PINP concentrations during teriparatide treatment correlate well with increases in skeletal activity assessed by radioisotope bone scans and quantitative bone histomorphometry parameters. Individuals treated with teriparatide in clinical trials usually experienced an increase in PINP > 10 mcg/L from baseline, while those given placebo usually did not. In the clinical setting, patients experiencing a significant increase in PINP > 10 mcg/L after initiating teriparatide therapy may receive an earlier confirmation of anabolic effect, while those who do not may be assessed for adherence, proper injection technique, or undetected secondary conditions that might mitigate an anabolic response. PINP monitoring may provide information supplemental to BMD monitoring and be a useful aid in managing patients receiving anabolic osteoporosis treatment in the same way that biochemical markers of bone resorption are useful in monitoring antiresorptive therapy. This review examines PINP as a biological response marker during teriparatide treatment for osteoporosis.

Original languageEnglish (US)
Pages (from-to)2159-2171
Number of pages13
JournalOsteoporosis International
Volume25
Issue number9
DOIs
StatePublished - 2014

Fingerprint

Teriparatide
Collagen Type I
Osteoporosis
Biomarkers
Bone Density
Therapeutics
Bone and Bones
Placebos
Clinical Trials
Anabolic Agents
Bone Remodeling
Bone Resorption
Osteoblasts
Radioisotopes
Injections

Keywords

  • Anabolics
  • Biochemical markers of bone turnover
  • Osteoporosis
  • PINP
  • Teriparatide

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

PINP as a biological response marker during teriparatide treatment for osteoporosis. / Krege, J. H.; Lane, Nancy E; Harris, J. M.; Miller, P. D.

In: Osteoporosis International, Vol. 25, No. 9, 2014, p. 2159-2171.

Research output: Contribution to journalArticle

Krege, J. H. ; Lane, Nancy E ; Harris, J. M. ; Miller, P. D. / PINP as a biological response marker during teriparatide treatment for osteoporosis. In: Osteoporosis International. 2014 ; Vol. 25, No. 9. pp. 2159-2171.
@article{b15dc6ce171f46b1a98d84418ee2f0a1,
title = "PINP as a biological response marker during teriparatide treatment for osteoporosis",
abstract = "Postmenopausal women with severe osteoporosis may require treatment with the bone anabolic drug teriparatide. While changes in bone mineral density (BMD) are one measure of response, BMD changes often require a minimum of one year to observe measureable changes. Biochemical markers of bone turnover change within 1 to 3 months of initiating osteoporosis therapy. Monitoring with a marker such as procollagen type I N propeptide (PINP), an osteoblast-derived protein, during teriparatide treatment may provide clinically useful information for managing patients with osteoporosis. Clinical trials have shown consistent increases in PINP within 3 months of initiating teriparatide, increases that are significantly greater than placebo and significantly different from baseline. Increases in PINP concentrations during teriparatide treatment correlate well with increases in skeletal activity assessed by radioisotope bone scans and quantitative bone histomorphometry parameters. Individuals treated with teriparatide in clinical trials usually experienced an increase in PINP > 10 mcg/L from baseline, while those given placebo usually did not. In the clinical setting, patients experiencing a significant increase in PINP > 10 mcg/L after initiating teriparatide therapy may receive an earlier confirmation of anabolic effect, while those who do not may be assessed for adherence, proper injection technique, or undetected secondary conditions that might mitigate an anabolic response. PINP monitoring may provide information supplemental to BMD monitoring and be a useful aid in managing patients receiving anabolic osteoporosis treatment in the same way that biochemical markers of bone resorption are useful in monitoring antiresorptive therapy. This review examines PINP as a biological response marker during teriparatide treatment for osteoporosis.",
keywords = "Anabolics, Biochemical markers of bone turnover, Osteoporosis, PINP, Teriparatide",
author = "Krege, {J. H.} and Lane, {Nancy E} and Harris, {J. M.} and Miller, {P. D.}",
year = "2014",
doi = "10.1007/s00198-014-2646-0",
language = "English (US)",
volume = "25",
pages = "2159--2171",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "9",

}

TY - JOUR

T1 - PINP as a biological response marker during teriparatide treatment for osteoporosis

AU - Krege, J. H.

AU - Lane, Nancy E

AU - Harris, J. M.

AU - Miller, P. D.

PY - 2014

Y1 - 2014

N2 - Postmenopausal women with severe osteoporosis may require treatment with the bone anabolic drug teriparatide. While changes in bone mineral density (BMD) are one measure of response, BMD changes often require a minimum of one year to observe measureable changes. Biochemical markers of bone turnover change within 1 to 3 months of initiating osteoporosis therapy. Monitoring with a marker such as procollagen type I N propeptide (PINP), an osteoblast-derived protein, during teriparatide treatment may provide clinically useful information for managing patients with osteoporosis. Clinical trials have shown consistent increases in PINP within 3 months of initiating teriparatide, increases that are significantly greater than placebo and significantly different from baseline. Increases in PINP concentrations during teriparatide treatment correlate well with increases in skeletal activity assessed by radioisotope bone scans and quantitative bone histomorphometry parameters. Individuals treated with teriparatide in clinical trials usually experienced an increase in PINP > 10 mcg/L from baseline, while those given placebo usually did not. In the clinical setting, patients experiencing a significant increase in PINP > 10 mcg/L after initiating teriparatide therapy may receive an earlier confirmation of anabolic effect, while those who do not may be assessed for adherence, proper injection technique, or undetected secondary conditions that might mitigate an anabolic response. PINP monitoring may provide information supplemental to BMD monitoring and be a useful aid in managing patients receiving anabolic osteoporosis treatment in the same way that biochemical markers of bone resorption are useful in monitoring antiresorptive therapy. This review examines PINP as a biological response marker during teriparatide treatment for osteoporosis.

AB - Postmenopausal women with severe osteoporosis may require treatment with the bone anabolic drug teriparatide. While changes in bone mineral density (BMD) are one measure of response, BMD changes often require a minimum of one year to observe measureable changes. Biochemical markers of bone turnover change within 1 to 3 months of initiating osteoporosis therapy. Monitoring with a marker such as procollagen type I N propeptide (PINP), an osteoblast-derived protein, during teriparatide treatment may provide clinically useful information for managing patients with osteoporosis. Clinical trials have shown consistent increases in PINP within 3 months of initiating teriparatide, increases that are significantly greater than placebo and significantly different from baseline. Increases in PINP concentrations during teriparatide treatment correlate well with increases in skeletal activity assessed by radioisotope bone scans and quantitative bone histomorphometry parameters. Individuals treated with teriparatide in clinical trials usually experienced an increase in PINP > 10 mcg/L from baseline, while those given placebo usually did not. In the clinical setting, patients experiencing a significant increase in PINP > 10 mcg/L after initiating teriparatide therapy may receive an earlier confirmation of anabolic effect, while those who do not may be assessed for adherence, proper injection technique, or undetected secondary conditions that might mitigate an anabolic response. PINP monitoring may provide information supplemental to BMD monitoring and be a useful aid in managing patients receiving anabolic osteoporosis treatment in the same way that biochemical markers of bone resorption are useful in monitoring antiresorptive therapy. This review examines PINP as a biological response marker during teriparatide treatment for osteoporosis.

KW - Anabolics

KW - Biochemical markers of bone turnover

KW - Osteoporosis

KW - PINP

KW - Teriparatide

UR - http://www.scopus.com/inward/record.url?scp=84906303588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906303588&partnerID=8YFLogxK

U2 - 10.1007/s00198-014-2646-0

DO - 10.1007/s00198-014-2646-0

M3 - Article

C2 - 24599274

AN - SCOPUS:84906303588

VL - 25

SP - 2159

EP - 2171

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 9

ER -